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Abstract
This survey showed low rates of HBV chronic infection in HIV-infected and
uninfected children living in a RLS of KZN province. The vertical and horizontal
transmissions before 5 years of age decreased in both cohorts since the
introduction of the HBV vaccine. Due to their weaker immune system, HIV-
infected children had lower anti-HBs rates than the HIV-uninfected patients.
Without establishing regular monitoring of their immunity and adaptation of the
vaccine schedule, prevalence of HBV could stay high in SA despite optimal
vaccination coverage in HIV-infected patients. 1.World Health Organization,
2014. HIV/AIDS (Accessed January 2016). http://www.who.int/hiv/en/ 2.Phung
BC, Sogni P, Launay O. 2014 Hepatitis B and human immunodeficiency virus
co-infection. World J Gastroenterol. 14;20(46):17360-7. 3.Healy SA, Gupta S,
Melvin AJ. 2013. HIV/HBV coinfection in children and antiviral therapy. Expert
Rev Anti Infect Ther. 11(3):251-63. 4.Amponsah-Dacosta E, Lebelo RL, Rakgole
JN, Burnett...
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 One hundred eighty-six HIV-infected children; 84 females (45.1%), with a median age of 9.1 years (range 6,5 to 14,8 years) were included in this study. 
Patients were distributed in 2 subgroups: the 5-10 years (103 children) and the 11-15 years (80 children). One hundred seventeen HIV-uninfected children; 44 
females (37.6%), with a median age of 9.0 years (range 5.8 to 15.0 years) were enrolled. Same distribution was done as in the other cohort: the 5-10 years (74 
patients) and the 11-15 years (34 children) subgroups.  
 Non-significantly higher rates of HBV infection were found in the HIV-infected (2,1%) compared to the HIV-uninfected cohort (0%) (p=0.3). Prevalence of 
HBV infection did not increase with age in both cohorts (p=0.8). Serological response to immunization was shown in 15.8% and 61.1% of HIV-infected and 
uninfected children respectively (p<0,001). 
 This survey aims firstly to describe the prevalence of Human-Immunodeficiency-Virus / Hepatitis-B-virus (HIV/HBV) co-infection in children living in a 
resource limited setting of the Kwazulu-Natal (KZN) province. Secondly, to compare the HBV vaccination response in HIV infected and uninfected children from 
this same region.  
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 Among the estimated 35 million(1) people affected by the Human Immunodeficiency Virus (HIV) worldwide, approximately 2-4 million are chronic carriers 
of Hepatitis B Virus (HBV)(2). HIV/HBV coinfection worsens the natural progress of HBV infection because it decreases the chance to clear acute HBV 
infection, induces faster progression to cirrhosis and a higher risk of hepatocarcinoma(3). Since 2000, only two studies(4-5) described the prevalence of chronic 
HBV (1,2-1,7%) in HIV-infected children living in South Africa (SA) (Gauteng and North West provinces).  
HIV infected HIV-uninfected  
5-10 years 11-15 years Total 5-10 years 11-15 years Total 
Ongoing infection 
(isolated HBsAg ) 
0/103 
(0%) 
1/80 
(1.3%) 
1/183 
(0.5%) 
0/74 
(0%) 
0/34 
(0%) 
0/108 
(0%) 
Past or ongoing infection 
 (HBsAg or anti-HBc with anti-HBs)   
2/103 
(1.9%) 
2/80 
(2.5%) 
4/183 
(2.1%) 
0/74 
(0%) 
0/34 
(0%) 
0/108 
(0%) 
HIV infected HIV-uninfected  
5-10 years 11-15 years Total 5-10 years 11-15 years Total 
Vaccinated against HBV  21/103 
(20.4%) 
8/80 
(10%) 
29/183 
(15.8%) 
49/74 
(66.2%) 
17/34 
(50%) 
66/108 
(61.1%) 
Conclusion 
 This survey showed low rates of HBV chronic infection in HIV-infected 
and uninfected children living in a RLS of KZN province. The vertical and 
horizontal transmissions before 5 years of age decreased in both cohorts 
since the introduction of the HBV vaccine. Due to their weaker immune 
system, HIV-infected children had lower anti-HBs rates than the HIV-
uninfected patients. Without establishing regular monitoring of their 
immunity and adaptation of the vaccine schedule, prevalence of HBV 
could stay high in SA despite optimal vaccination coverage in HIV-infected 
patients.  
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